Solve Therapeutics, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Solve is developing novel antibody-drug conjugates (ADCs) engineered for selectivity and optimized payload delivery, as well as novel patient-selection diagnostics.

Our team’s approach to ADCs is built on our foundational understanding of how the components of the molecule – antibody, linker, and payload – can be optimized and work together synergistically to meaningfully improve the benefit-risk profile for patients.

ADCs have proven clinical value, but issues remain with off-target toxicity, sub-optimal payload delivery, and difficulties with patient selection. Solve’s technologies are designed to address these challenges through cutting-edge antibody engineering, a novel hydrophilic and highly stable linker system (CloakLink™), and an integrated diagnostic platform designed to help identify patients most likely to benefit from treatment.

Sign up for free to view info

Email Format Employee directory